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Armando M. De Palma,1 Hendrik Jan Thibaut,1† Lonneke van der Linden,2† Kjerstin Lanke,2
Ward Heggermont,1 Stephen Ireland,3 Robert Andrews,3 Murty Arimilli,3 Taleb H. Al-Tel,3
Erik De Clercq,1 Frank van Kuppeveld,2 and Johan Neyts1*
Rega Institute for Medical Research, University of Leuven, B-3000 Leuven, Belgium1; Department of Medical Microbiology,
Radboud University Nijmegen, Nijmegen Centre for Molecular Life Sciences, 6500 HB Nijmegen, The Netherlands2; and
Transtech Pharma, Inc., 4170 Mendenhall Oaks Parkway, High Point, North Carolina 272653
Received 15 July 2008/Returned for modification 19 September 2008/Accepted 19 January 2009
A novel compound, TTP-8307, was identified as a potent inhibitor of the replication of several rhino- and
enteroviruses. TTP-8307 inhibits viral RNA synthesis in a dose-dependent manner, without affecting polypro-
tein synthesis and/or processing. Drug-resistant variants of coxsackievirus B3 were all shown to carry at least
one amino acid mutation in the nonstructural protein 3A. In particular, three mutations located in a non-
structured region preceding the hydrophobic domain (V45A, I54F, and H57Y) appeared to contribute to the
drug-resistant phenotype. This region has previously been identified as a hot sport for mutations that resulted
in resistance to enviroxime, the sole 3A-targeting enterovirus inhibitor reported thus far. This was corrobo-
rated by the fact that TTP-8307 and enviroxime proved cross-resistant. It is hypothesized that TTP-8307 and
enviroxime disrupt proper interactions of 3A(B) with other viral or cellular proteins that are required for
efficient replication.
Enteroviruses comprise several pathogens that are impli-
cated in an large variety of clinical manifestations that range
from mild illnesses to more serious or even life-threatening
diseases, such as meningitis, encephalitis, myocarditis, pancre-
atitis, acute paralysis, or neonatal sepsis (30, 40). Enteroviruses
are small, nonenveloped, and spherical in shape, with a diam-
eter of about 30 nm. The icosahedrally shaped capsids are
assembled from 60 protomers, each composed of four struc-
tural proteins, designated VP1 (for viral protein 1), VP2, VP3,
and VP4 (38, 39). The enteroviral genome consists of a single-
stranded, positive-sense RNA of approximately 7,500 bases in
length. The coding region of the viral genome is divided into
three primary precursor molecules which contain the four
structural (derived from P1) and 10 nonstructural viral pro-
teins (derived from P2 and P3).
The nonstructural protein 3A and its precursor 3AB are
derived from P3 and are indispensable for viral replication. A
feature of 3A that has been the subject of many studies is its
ability to serve as a membrane anchor through the presence of
a 22-residue hydrophobic domain that forms an amphipathic
helix near its C terminus (25). In infected cells, both 3A and
3AB are found in association with membranes (17). In the
context of the viral replication complex, 3AB serves to deliver
the basic protein VPg (3B) at the 5 ends of plus- and minus-
strand RNA during replication (18, 41) and, hence, to recruit
the other proteins of the replication complex to the cellular
membranes, the site of viral replication. The 3B protein then
serves as a primer for the initiation of RNA synthesis, probably
only after it has been cleaved from the 3A portion and not
when it is still in the 3AB membrane-bound state (17). Cleav-
age of 3AB is mediated by 3Cpro/3CDpro and can only occur
when the protein is membrane bound (26). Moreover, this
proteolysis was shown to be enhanced in the presence of pu-
rified 3AB but not 3A (26, 31, 49). Stimulation of catalytic
activity by 3AB has also been observed for the 3Dpol, both
when 3AB is membrane bound and purified, and this has been
suggested to occur via stabilization of the primer-template/
3Dpol complex (26, 28, 35–37). 3AB but not 3A shows nonspe-
cific RNA-binding activity but binds specifically to the 5 RNA
cloverleaf of the viral RNA genome when it is complexed with
3CDpro (20, 28, 48). The protein also binds to the 3 untrans-
lated region but, in contrast to binding at the 5 cloverleaf,
binding at the 3 untranslated region can also occur in the
absence of other proteins (20). Moreover, 3AB has been
shown to induce membrane permeability in bacterial but not
mammalian cells (1, 24, 25, 29), to induce membrane alter-
ations in the endoplasmic reticulum (ER) (15), to form ho-
modimers (26, 42, 47), and to be involved in host range patho-
genicity (2, 27, 33, 34).
Apart from these features that are directly or indirectly
associated with viral replication, 3A and 3AB are also involved
in processes that specifically affect the host cell. It is well
documented that protein 3A is able to interfere with cellular
protein secretion via inhibition of ER-to-Golgi transport, caus-
ing accumulation of proteins otherwise destined for export (4,
13, 14). Determinants for this feature are located at the N
terminus (4, 13, 44–46). This inhibition of ER-to Golgi trans-
port has been shown to reduce or inhibit the secretion of
antiviral cytokines such as interleukin-6, interleukin-8, and
beta interferon (12), the concentration of tumor necrosis factor
receptor on the surfaces of infected cells (32), and the presen-
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tation of antigen in the context of major histocompatibility
complex class I molecules (7). In doing so, ER-to-Golgi trans-
port inhibition in infected cells might help in evading the host
cell’s immune response and, hence, promote viral replication
in an indirect way, although this inhibition is not required for
efficient viral replication per se (12, 13).
The indispensable presence of 3A(B) during viral replication
makes this protein an attractive candidate as a target for inhi-
bition of viral replication. Thus far, only one compound (en-
viroxime) has been reported to target protein 3A (8, 22, 23).
Despite its potent antiviral activity, however, the development
of this compound was halted, mainly because of toxicity and an
unfavorable pharmacokinetic profile (6). We here report on a
novel compound (TTP-8307) that was identified in a screening
campaign for inhibitors of the replication of enteroviruses. The
compound appeared to be a potent inhibitor of the replication
of several rhino- and enteroviruses.
MATERIALS AND METHODS
Cells and viruses. Vero cells (ATCC CCL-81), Buffalo green monkey (BGM)
cells (ECACC 90092601), and HeLa cells (ATCC CCL-2) were grown in minimal
essential medium (Gibco, Merelbeke, Belgium) supplemented with 10% heat-
inactivated fetal bovine serum (Integro, Leuvenheim, The Netherlands), 5%
bicarbonate (Gibco), and 5% L-glutamine (Gibco). Cells were grown at 37°C in
a 5% CO2 incubator. Coxsackievirus B3 (CVB3) was derived from plasmid
pCB53/T7, which contains a full-length cDNA of CVB3 strain Nancy behind a T7
RNA promoter (45). For assays involving virus growth, 2% fetal bovine serum
was used instead of 10% fetal bovine serum. Rhinoviruses were provided by K.
Andries, and the poliovirus Sabin 1, 2, and 3 strains were from B. Rombaut
(Vrije Universiteit Brussels, Brussels, Belgium). Enterovirus 71 (BrCr) and cox-
sackieviruses A16 (G-10) and A21 (Coe) were obtained from the Rijksinstituut
voor Volksgezondheid en Milieu (The Netherlands).
Compounds. The synthesis of TTP-8307 (436 g/mol) will be reported else-
where. The purity of the compound used in the present study was determined to
be 96% by spectroscopic (nuclear magnetic resonance) and chromatographic
(liquid chromatography-mass spectrometry) techniques. TBZE-029 and envi-
roxime were synthesized as reported elsewhere (10). Guanidine hydrochloride
was from Sigma (Bornem, Belgium). All compounds were solubilized in dimethyl
sulfoxide at 20 mM and stored at 4°C. For working solutions, the dimethyl
sulfoxide stocks were diluted in minimal essential medium to the desired con-
centration.
In vitro RNA transcription and transfection. Prior to in vitro RNA transcrip-
tion, plasmid p53CB3/T7 was linearized with SalI (Promega, Leiden, The Neth-
erlands). The digest was purified (gel and PCR purification kit; Promega), and
2.5 g of DNA was used for in vitro RNA transcription (Ribomax large-scale
RNA production system; Promega). The transcription reaction was carried out at
37°C for 4 h, after which the reaction mixture was DNase treated, and RNA was
purified (RNA Cleanup System; Qiagen, Venlo, The Netherlands). Transfec-
tions were carried out in 25-cm2 culture flasks in Vero cells, grown to 75%
confluence. Reaction mixtures, containing 2 ml of OptiMEM (Gibco), 2.5 g of
purified RNA, and 10 l of DMRIE-C transfection reagent (Invitrogen) were
incubated for 4 h at 37°C. Subsequently, the medium was replaced with fresh
growth medium and incubated until the cultures exhibited an extensive cyto-
pathic effect (CPE). At this point, the flasks were subjected to three rounds of
freezing-thawing, and the collected supernatant was titrated for infectious virus
content by endpoint titration.
Multicycle CPE reduction assays. The antiviral activity of the selected com-
pound was initially determined by using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenol)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt]-based
CPE reduction assay. Briefly, cells grown to confluence in 96-well plates were
infected with 100 50% cell culture infective doses (CCID50) of virus. After an
adsorption period of 2 h at 37°C (35°C for rhinovirus), the virus was removed,
and serial dilutions of the compounds were added. The cultures were further
incubated at 37°C for 3 days, until complete CPE was observed in the infected
and untreated virus control (VC). After removal of the medium, 90 l of culture
medium and 10 l of MTS/PMS (Promega) were added to each well. After an
incubation period of 2 h at 37°C, the optical density at 498 nm (OD498) of each
well was read in a microplate reader. CPE values were calculated as follows: %
CPE 100 ([ODCC – ODviruscompound]/[ODCC – ODVC]). In these formulae,
ODCC corresponds to the optical density of the uninfected and untreated cell
cultures, ODVC represents the infected and untreated cell cultures, and
ODviruscompound are virus-infected cell cultures treated with a given concentra-
tion of compound. The 50% effective concentration (EC50) was defined as the
concentration of compound that resulted in 50% protection against virus-in-
duced CPE and was calculated by using logarithmic interpolation.
Viral plaque assays. For determination of viral plaques, Vero cells, grown to
confluence in six-well plates, were infected with CVB3 at 37°C with slight shaking
at 55 rpm. After 2 h, the virus was removed, the cells were washed twice with
phosphate-buffered saline (PBS), and the growth medium was replaced with agar
(final concentration, 0.4%) in the presence or absence of compound. After 3 to
4 days, plaques were visualized. Briefly, cells were fixed with 2 ml of a solution
containing 4% formaldehyde, after which the agar was removed. A 2% Giemsa
solution was used to stain the cells.
Analysis of viral RNA accumulation with subgenomic replicon pCB53/T7-Luc.
Accumulation of viral ()RNA was monitored by transfecting cells (in the
presence or absence of 25 M TTP-8307) with RNA derived from the SalI-
linearized plasmid pCB53/T7-Luc, which contains a subgenomic CVB3 replicon,
carrying a luciferase gene in place of the capsid coding P1 region. At the
indicated times posttransfection, the cells were washed three times with PBS and
lysed with 75 l of lysis buffer. The luciferase activity was measured in a liquid
scintillation counter with the luciferase assay system according to the recommen-
dations of the manufacturer (Promega). The luciferase activity was expressed in
(relative) light units.
Quantitative analysis of CVB3 RNA by real-time qRT-PCR assays. Real-time
quantitative reverse transcription-PCR (qRT-PCR) was performed with an ABI
Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA).
Primers and probes were developed using Primer Express software (Applied
Biosystems) as described elsewhere (9). The following primers and probe were
used: a forward primer specific for nucleotides 2937 to 2957 (5-ACG AAT CCC
AGT GTG TTT TGG-3), a reverse primer specific for nucleotides 3003 to 2982
(5-TGC TCA AAA ACG GTA TGG ACA T-3), and a TaqMan probe specific
for nucleotides 2960 to 2977 (5-FAM-CGA GGG AAA CGC CCC GCC-
TAMRA-3). Each reaction was performed in 25 l of a PCR reagent mixture
(One-Step qRT-PCR mix; Eurogentec, Seraing, Belgium) containing 900 nM
concentrations of each primer and 200 nM concentrations of the specific TaqMan
probe. The PCR consisted of an RT step (30 min at 48°C), a Taq activation step
(10 min at 95°C), and 50 cycles of denaturation (15 s at 94°C) and annealing/
extension (1 min at 60°C). The RNA copy number in each sample was deter-
mined by a standard curve generated from increasing copy numbers of a syn-
thetic transcript corresponding to 67 nucleotides of the CVB3 genome.
Time of drug addition studies. Vero cells, grown to confluence in 24-well
culture plates, were infected with 104 CCID50 of coxsackievirus B3. After an
adsorption period of 1 h at 37°C, virus was removed and replaced with 500 l of
growth medium. At 1-h intervals, 500 l of medium containing a 2 compound
solution was added (final concentration, 25 M). At 8 h postinfection, the
supernatant, as well as intracellular RNA of the infected cultures, was collected,
and viral RNA was quantified by means of real-time qRT-PCR. The levels of
viral RNA were compared to their untreated controls.
Analysis of viral polyprotein processing in vivo. BGM cells, grown to conflu-
ence in 24-well plates, were infected with coxsackievirus B3 at a multiplicity of
infection of 50. At 5 h postinfection, the medium was replaced with 300 l of
methionine-free medium. Thirty minutes later, the cultures were pulse-labeled in
methionine-free medium containing 1 l of Met35[S]/well in the absence or
presence of TTP-8307 (25 M final concentration) for 30 min. At 6 h postinfec-
tion cells were washed once with PBS and lysed in 75 l of cold lysis buffer
containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Nonidet
P-40, and 0.05% sodium dodecyl sulfate (SDS). Translation products were ana-
lyzed on a 12.5% polyacrylamide gel containing SDS. The gels were fixed in 30%
methanol–10% acetic acid, rinsed in dimethyl sulfoxide, fluorographed with 20%
2,5-diphenyloxazole in dimethyl sulfoxide, dried, and exposed to Kodak XAR
film.
Generation of TTP-8307-resistant coxsackievirus. Drug-resistant virus was
generated by growing virus in the presence of gradually increasing concentrations
of TTP-8307 on confluent Vero cultures in 48-well culture plates. After 4 to 5
days of culture, culture supernatant was collected from cultures that exhibited
full CPE in the presence of the highest concentration of compound used. This
virus was used for a successive round of infection, a procedure that was repeated
until full CPE was noticed at concentrations of TTP-8307 (20 M) that did not
allow replication of wild-type virus. Subsequently, the resistant virus pool was
subjected to plaque purification (in the presence of 20 M compound), and
individual clones were used for sequencing.
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Site-directed mutagenesis. Four mutant CVB3 clones were constructed, con-
taining single amino acid replacements at positions 8, 45, 54, and 57 in protein
3A. The four clones were designated mutant 1 (3A[I8T]), mutant 2 (3A[V45A]),
mutant 3 (3A[I54F]), and mutant 4 (3A[H57Y]). The corresponding synthetic
oligonucleotides (and their complementary reverse oligonucleotides) were used
for site-directed mutagenesis: (i) 5-GGA CCA CCA GTA TAC AGA GAG
ACC AAA ATT AGC GTT GCA CC-3, (ii) 5-GAA AAA GGA TGG TTG
GCT CCT GAG ATC AAC TCC ACC C-3, (ii) 5-C TCC ACC CTC CAA TTT
GAG AAA CAT GTC AGT CGG G-3, and (iv) 5-CC CTC CAA ATT GAG
AAA TAT GTC AGT CGG GCT TTC-3. The mutated sequences are under-
lined. Site-directed mutagenesis was performed with plasmid pCB53/T7 using
the XL-Blue large site-directed mutagenesis kit (Stratagene, Amsterdam, The
Netherlands), according to the manufacturer’s instructions. After mutagenesis,
the individual clones were verified by sequencing. Next, a 711-bp fragment
containing the desired mutations was isolated using the enzymes BssHII and
XbaI and reintroduced in an original, nonmutagenized clone of the same plasmid
pCB53/T7. From these mutants, RNA transcripts and infectious viruses were
generated as described earlier.
Sequencing. PCR fragments that cover the entire CVB3 genome were gener-
ated and analyzed by using the cycle sequencing method (ABI Prism BigDye
terminator cycle sequencing ready reaction kit). Both DNA strands were se-
quenced. Sequencing data were obtained with an ABI 373 automated sequence
analyzer (Applied Biosystems), and sequences were analyzed with the Vector
NTI software (Invitrogen).
RESULTS
TTP-8307 inhibits replication of several enteroviruses. TTP-
8307 was identified in a screening campaign as a selective
inhibitor of CVB3 replication in Vero cells. The effect of TTP-
8307 (Fig. 1A) was next evaluated against a selection of entero-
and rhinoviruses in an MTS-based CPE reduction assay. TTP-
8307 inhibits the replication of coxsackievirus B3 and the three
poliovirus Sabin strains, as well as coxsackieviruses A16 and
A21 (Table 1). TTP-8307 inhibits human rhinoviruses (HRVs)
2, 29, 39, 45, 63, and 85, but not other rhinovirus serotypes
(HRV serotypes 9, 14, 15, 41, 42, 70, 72, 86, and 89) or
enterovirus 71. Coxsackievirus B3 (CVB3), the prototype of
the non-polio enteroviruses, was used to further study the
particular characteristics of the antiviral activity of TTP-8307.
TTP-8307 inhibited CVB3 replication in a dose-dependent
manner (Fig. 2) when monitored either by (i) CVB3-induced
CPE formation (Fig. 2A) or (ii) CVB3-induced plaque forma-
tion (Fig. 2B),
TTP-8307 acts at a stage that coincides with CVB3 viral
RNA replication and polyprotein synthesis/processing. Time
of drug addition studies were carried out to obtain a first
indication about the stage in the viral replication cycle where
TTP-8307 exerts its antiviral activity. Maximal inhibition of
viral replication was maintained when the drug was added
within the first 3 h postinfection (Fig. 3A). The addition of the
drug at a time point later than 3 h postinfection, which coin-
cides with the onset of viral RNA synthesis, resulted in a
gradual decrease in antiviral activity. It can thus be concluded
that TTP-8307 does not hamper early (attachment, entry, and
uncoating) or late (assembly and release) events but rather
interferes with intermediate processes, such as viral RNA rep-
lication, viral polyprotein synthesis, and/or processing.
TTP-8307 inhibits accumulation of CVB3 viral RNA. The
accumulation of viral RNA in the absence or presence of
TTP-8307 was monitored upon transfection of BGM cells with
an infectious subgenomic replicon of CVB3 (in which the P1
region was replaced with a luciferase marker). Transfection in
the presence of TTP-8307 (25 M) led to a complete inhibition
of viral RNA accumulation, whereas an increase in luciferase
activity was measured in the absence of compound (Fig. 3B).
The replication inhibitor guanidine hydrochloride (2 mM) was
included as a reference compound and resulted in the inhibi-
tion of viral RNA accumulation as well.
TTP-8307 does not affect CVB3 polyprotein synthesis or
processing. Viral protein synthesis and polyprotein processing
were monitored in a pulse-labeling experiment in the presence
(25 M) or absence of TTP-8307. From Fig. 3C it is evident
TABLE 1. Antiviral effect of TTP-8307 against selected entero-
and rhinoviruses
Virus
Mean EC50 (M)a  SD
TTP-8307 Enviroxime
Human enterovirus A
CVA16 (G-10) 0.85  0.08 0.12  0.01
EV71 (BrCr) 60 0.15  0.06
Human enterovirus B
CVB3 (Nancy) 1.2  0.1 1.9  1.5
Human enterovirus C
CVA21 (Coe) 5.34  0.93 0.48  0.42
Polioviruses
PV1 (Sabin) 0.51  0.05 0.19  0,24
PV2 (Sabin) 0.58  0.05 0.06  0,01
PV3 (Sabin) 0.27  0.23 0.04  0,02
Major group rhinoviruses
HRV9 50 0.038  0.001
HRV14 50 0.11  0.04
HRV15 50 0.042  0.03
HRV39 0.65  0.51 0.028  0.01
HRV41 50 0.027  0.003
HRV42 50 0.11  0.05
HRV45 0.99  0.04 0.25  0.03
HRV63 0.091  0.054 0.027  0.001
HRV70 50 0.11  0.02
HRV72 50 0.72  0.03
HRV85 1.22  0.21 0.033  0.006
HRV86 50 0.14  0.03
HRV89 50 0.10  0.04
Minor group rhinoviruses
HRV2 0.80  0.12 0.026  0.022
HRV29 0.77  0.38 0.029  0.005
a Data are mean values for at least three independent experiments. The cyto-
toxicity of TTP-8307 was determined on confluent Vero and HeLa cells, and the
TC50 values (i.e., the 50% cytotoxic concentration) were 100 M. The com-
pound solubility limit in assay medium is 100 M.
FIG. 1. Structural formulae of TTP-8307 (A) and enviroxime (B).
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that a similar pattern of viral proteins was observed in the
presence or absence of TTP-8307. Thus, neither the rate of
protein synthesis nor the processing of viral proteins was af-
fected by the compound. This observation, together with the
observed effect of TTP-8307 in the subgenomic replicon, points
to the synthesis of viral RNA as the potential target of action
of TTP-8307.
TTP-8307 resistant CVB3 clones share mutations in the
nonstructural protein 3A. To identify the molecular target of
TTP-8307, drug-resistant CVB3 variants were selected. To this
end, CVB3 was cultured successively in the presence of in-
creasing concentrations of TTP-8307. After 10 passages, five
independently cultured pools of CVB3 were obtained that
replicated efficiently in the presence of TTP-8307 at concen-
trations that exceeded the EC50 more than 10-fold. The virus
pools thus obtained were plaque purified in the presence of 20
M TTP-8307 and one or several clones from each pool were
picked up. As such, 10 clones were selected for genotyping
(Table 2). Except for clone 1A, all clones carried mutations in
two or more different proteins, including 2A, 2B, 2C, 3A,
and/or 3D. A remarkable observation, however, was that all
clones carried at least one mutation in protein 3A. Further-
more, each of the following four mutations in 3A recurred in
different clones (either or not if they derived from the same
pool): I8T, V45A, V54A, and H57Y. In contrast, none of the
mutations observed in the other proteins occurred more than
once in clones that were derived from independently cultured
pools. Moreover, three of the four identified mutations in 3A
were located in a region that was previously shown to accumu-
late mutations involved in resistance to the 3A inhibitor envi-
roxime (see Discussion). The contribution of the 3A mutations
to the drug-resistant phenotype was therefore studied in more
detail.
Recombinant CVB3 3A mutants have plaque phenotypes
similar to those of wild-type virus. A plasmid (pCB53/T7)
encoding an infectious full-length CVB3 genome was used to
generate four recombinant clones carrying the four identified
mutations in protein 3A individually. These clones were des-
ignated mutant 1 (3A[I8T]), mutant 2 (3A[V45A]), mutant 3
(3A[I54F]), and mutant 4 (3A[H57Y]). Plaque assays with the
mutant viruses revealed that infection with these mutant vi-
ruses do not result in altered plaque phenotypes compared to
wild-type CVB3 (Fig. 4).
Recombinant CVB3 clones carrying mutations in 3A are
resistant to inhibition by TTP-8307 and enviroxime. Next, the
four recombinant mutant viruses were evaluated for their abil-
ity to form plaques in the presence of various concentrations of
TTP-8307. Two reference molecules were included as a con-
trol: enviroxime (previously reported to inhibit enterovirus
replication by targeting 3A) and the 2C inhibitor TBZE-029
(9). The graphs depicted in Fig. 5 represent PFU after infec-
tion of Vero cells with wild-type virus or the constructed 3A
mutants at a given concentration for a given compound.
In the absence of drug, all clones (as well as the wild type)
resulted in the formation of, on average, 10  104 to 15  104
plaques per ml. TTP-8307 at a concentration of 8 M or higher
completely prevented the formation of plaques in virus-in-
fected cultures, whereas the recombinant mutant clones were
still able to form plaques in the presence of TTP-8307 at these
concentrations. In particular, mutants 2 and 3 (and to a lesser
extent mutant 4) carrying amino acid mutations V45A and
I54F (and H57Y) were still able to generate progeny virus at
higher drug concentrations. Mutant 1 (I8T) remained rela-
tively sensitive to inhibition by TTP-8307. A comparable pat-
tern of (lack of) sensitivity of the variant mutants was observed
for enviroxime. Enviroxime- and TTP-8307-resistant mutants
can thus be considered cross-resistant. Finally, the sensitivity of
the different recombinant viruses was assessed in the presence
of TBZE-029, a compound that we recently reported to target
the nonstructural protein 2C. As expected, TBZE-029 was
equipotent in its inhibition of wild-type and mutant viruses.
Taken together, these data indicate that in particular 3A mu-
tations V45A, I54F, and H57Y confer resistance to TTP-8307.
DISCUSSION
We identified a novel compound, TTP-8307, that potently
inhibits the replication of several enteroviruses, including cox-
sackievirus B3 and poliovirus by interfering with the synthesis
of viral RNA. Contemplating the need for antivirals in the end
stages of the worldwide polio eradication (5, 11), TTP-8307
might be considered as an interesting compound for lead op-
FIG. 2. Dose-dependent inhibition of viral replication by
TTP-8307. Vero cell cultures infected with CVB3 were treated with
different concentrations of TTP-8307, and the effect on viral replica-
tion was monitored at day 3 postinfection. (A) Effect on virus-induced
CPE formation (using an MTS-based cell protection assay). (B) Plaque
reduction. The data represent averages the standard deviations (SD)
from three independent experiments.
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timization, given its potent inhibitory effect on the replication
of the three PV Sabin strains.
To determine the viral target of TTP-8307, resistant CVB3
variants were selected. Each clone carried at least one of the
following mutations in protein 3A: I8T, V45A, I54F, or H57Y.
These mutations were reintroduced in an infectious CVB3
full-length clone and the antiviral sensitivity of the resulting
viruses was studied. Mutants 2, 3, and 4 (carrying 3A mutations
V45A, I54F, or H57Y) were shown to form plaques in the
presence of concentrations of TTP-8307 that did not allow
replication of wild-type virus, confirming that these mutations
contribute to the observed resistance phenotype. The calcu-
lated EC90 values of TTP-8307 for inhibition of these mutant
viruses were ca. 8- to 10-fold higher than for wild-type CVB3.
Moreover, cross-resistance was observed with enviroxime. The
specificity of this resistance profile was corroborated by the fact
that a 2C-targeting compound (9, 10) inhibited the replication
of the mutants as efficiently as that of the wild-type virus.
Mutant I8T allowed for some very low replication in the pres-
ence of TTP-8307 and enviroxime. The viruses carrying the
engineered mutations proved phenotypically (formation of
plaques) comparable to the wild-type virus, suggesting no del-
eterious effects of the 3A mutations on viral replication. It
should be noted, however, that the reconstructed mutants car-
rying single amino acid mutations in 3A did not exhibit the
same high degree of resistance that we observed with the
naturally selected clones. In fact, all naturally selected clones
FIG. 3. TTP-8307 inhibits accumulation of CVB3 viral RNA without affecting polyprotein processing. (A) Time of drug addition. TTP-8307 (25
M) was added to CVB3-infected cell cultures at 1-h intervals, starting at 1 h before infection. At 8 h postinfection, the time needed for a single
replication cycle, intra- and extracellular viral RNA was collected and quantified by means of real-time qRT-PCR. Values were standardized to
the 0-h time point. The data represent averages  the SD from two independent experiments. (B) Analysis of viral RNA accumulation with
subgenomic replicon pCB53/T7-Luc. Accumulation of viral ()RNA was monitored after transfection of BGM cells (in the presence or absence
of TTP-8307) with RNA derived from a chimeric subgenomic replicon (pCB53/T7-Luc). At the indicated times posttransfection, the luciferase
activity was quantified and expressed in (relative) light units [(R)LU]. The data represent averages the SD from three independent experiments.
(C) Effect of TTP-8307 on polyprotein processing. BGM cells grown to confluence in 24-well plates were infected with CVB3. At 5h30 min
postinfection, cells were pulse-labeled for 30 min with Met35[S] after starvation in methionine-free medium for 30 min, either in the presence (25
M) or absence of TTP-8307. Cells were lysed and translation products were analyzed by SDS-polyacrylamide gel electrophoresis. The data
represent averages  the SD from three independent experiments.
TABLE 2. Mutations in TTP-8307-resistant CVB3 clones
Passage
line
(pool)
Clone
Amino acid mutation(s)
2A 2B 2C 3A 3D
1 A I8T, V45A
B N26D H57Y
C N26D H57Y
2 A E59Q I112V I54F
B E64A I8T
C E120Q S109G I54F D397E
3 A R41K V45A
B H57Y V8I, G124R
4 A L47Q, K51N H57Y
5 A I92V H57Y
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were selected and plaque purified in the presence of 20 M
TTP-8307 and, hence, had EC90 values of 20 M. None of
the reconstructed viruses carrying single amino acid mutations,
however, reached EC90 values of 20 M. It may therefore be
assumed that other sequence variations (in proteins different
than 3A) may contribute to a further increase in the level of
resistance to TTP-8307.
An amino acid sequence alignment of the 3A proteins of
CVB3, PV1, HRV2, and HRV14 is depicted in Fig. 6. Glo-
bally, two major regions were reported to be important for
resistance to enviroxime (3, 22, 23). The first region involves
residues in the hydrophobic domain of 3A, located near its C
terminus, whereas the second region is located between amino
acids 40 and 60. This latter region, preceding the hydrophobic
domain (underlined in green in Fig. 6), has been predicted to
be unstructured, based on the nuclear magnetic resonance
structure of the soluble domain of PV protein 3A (42). Re-
markably, the 3A mutations that we identified in the present
study as major determinants for resistance to TTP-8307
(V45A, I54F, and H57Y) were also located in this region
(arrows in Fig. 6A; residues highlighted in Fig. 6C). Moreover,
the very same H57Y mutation that was identified in TTP-8307-
resistant CVB3 was also detected in enviroxime-resistant
CVB3. In contrast to enviroxime, no mutations were detected
in the hydrophobic domain of 3A in TTP-8307-resistant CVB3.
This may be explained by the fact that TTP-8307 and envi-
roxime interact with the same region of 3A but that, given their
different chemical structure, the precise molecular interactions
with the various amino acids in this region may be (partially)
different. Single amino acid mutations in the nonstructured
region (amino acids 40 to 60) were shown to be sufficient to
confer a certain degree of resistance to enviroxime (22, 23),
corroborating our present observations. Florez de Sessions et
al. observed that a chimeric CVB3 carrying an HRV2 internal
ribosome entry site and that was adapted for growth in a
neuroblastoma cell line carried the mutation V45A in 3A (16).
Similar observations were described by Harris and Racaniello
(19), who identified mutations in 3A at amino acid positions
that correspond to CVB3 residues 42 and 44 in HRV39 that
was adapted for growth in mouse cells. None of these muta-
tions substantially affected viral plaque formation (16, 19),
which is in line with our observations. The unstructured region
preceding the hydrophobic domain may thus allow for adap-
tation of the virus to selective pressure of different kinds (e.g.,
antivirals or a changing host) without compromising viral
growth.
A question that remains to be answered is what determines
the spectrum of activity of TTP-8307. An alignment of the 3A
amino acid sequence of TTP-8307-sensitive and -resistant vi-
ruses did not reveal any particular amino acids or regions in 3A
that determined whether or not a virus would be inhibited by
TTP-8307 (data not shown). For example, CVA16 and entero-
FIG. 4. Plaque phenotypes of wild-type CVB3 and recombinant
clones.
FIG. 5. Viral replication of wild-type and recombinant viruses in
the presence of TTP-8307, enviroxime and TBZE-029. Each graph
represents the number of PFU produced by wild-type CVB3 or by any
of the four constructed 3A mutants—3A[I8T], 3A[V45A], 3A[I54F], and
3A[H57Y]—at a given compound concentration. Calculated EC90 values
represent averages  the SD from five independent experiments. ,
P 	 0.05.
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virus 71 (TTP-8307 sensitive and resistant, respectively) share
the N-terminal 3A amino acid sequence entirely, despite their
difference in sensitivity. A possible explanation might be that
3A is a key protein in the replication inhibition, but that pro-
teins other than 3A are involved in this inhibition as well.
Therefore, despite the fact that 3A was identified as a prime
target for TTP-8307 as well as for enviroxime, the precise
mechanism of action for inhibition of viral inhibition by these
compounds remains to be elucidated. In contrast to 2CATPase,
3C(D)pro, and 3Dpol, protein 3A is not thought to be associated
with any enzymatic activity and, hence, the inhibition of this
protein by a compound cannot be assessed in a simple in vitro
enzymatic assay. Rather than hampering a catalytic reaction,
3A-targeting drugs are likely to mediate hindrance of certain
interactions of 3A with other (viral or cellular) proteins in the
viral replication complex, an idea than can be supported given
the multitude of interactions that have been ascribed to this
protein (43, 50). For enviroxime, it was recognized that repli-
cation inhibition is probably not only occurring through tar-
geting of 3A but may also depend on interactions with other
proteins in the replication complex (3). More precisely, a
HRV14 mutant was identified that carried, in addition to 3A
mutations, mutations in 3Dpol. These additional mutations re-
sulted in a higher degree of resistance. These findings are in
line with our observations that several of the identified mutants
carry amino acid changes in proteins other than 3A (Table 2).
However, these mutations were identified in various proteins
(2A, 2B, 2C, and 3D) and at different residue positions. Based
on the hypothesis that TTP-8307 and enviroxime interfere with
3A through inhibition of certain interactions with other pro-
teins, one could postulate that mutations in 3A are necessary
for resistance, but that the level of resistance is increased by
additional mutations in other proteins (that interact with 3A).
Interestingly, recently CVB3 was selected that was resistant to
amiloride; resistance was shown to map to the 3Dpol, but the
resistant variant carried also a mutation at 3A residue I54
(similar to clones 4 and 6 identified in the present study) (21).
The contribution of this 3A mutation to the resistant pheno-
type was however, not further determined.
In conclusion, we identified a novel enterovirus replication
inhibitor that targets the nonstructural protein 3A. Mutations
conferring the highest levels of resistance mapped to the non-
structured region preceding the hydrophobic domain, a region
that was also reported to contain mutations in enviroxime-
resistant viruses. The precise mechanism of viral inhibition by
targeting 3A remains to be addressed in future studies.
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